Glaxo Wellcome Inc.

Burroughs Wellcome Co.

David J Porter

Thomas A Krenitsky

Thomas Spector

Saad George Rahim

The present invention relates to a group of 5-substituted uracil derivatives which are inactivators of uracil reductase and which are particularily useful in cancer chemotherapy, especially in combination with antimetabolite antineoplastic agents such as 5-fluorouracil (5-FU).

Uracil reductase inactivators

Pharmaceutical compositions containing 5-substituted uracil compounds are disclosed. The compositions are preferably in the form of a tablet or capsule.

Pharmaceutical compositions of 5-substituted uracil compounds

The 5'-O-proprionyl and 5'-O-butyryl esters of 2-amino-6-methoxy-9-(B-D-arabinofuranosyl)-9H-purine useful as inhibitors of varicella zoster virus.

5'-O-propionyl and 5'-O-butyryl esters of

The compound 9-B-D-arabinofuranosyl-2-amino-6-methoxy-9H-purine along with its 5'-acetyl and 5'-(4-methoxy-4-oxobutyryl derivatives are disclosed as inhibitors of Varicella Zoster virus (VZV).

Growing community of inventors

Raleigh, NC, United States of America

David J Porter